Technology platform for development of multi-component preservation solution
多组分保存解决方案开发技术平台
基本信息
- 批准号:8582171
- 负责人:
- 金额:$ 21.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-01 至 2015-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse eventAlgorithmsAmino AcidsArrhythmiaBiological PreservationBone necrosisCardiovascular DiseasesCartilageCategoriesCell Membrane StructuresCell TherapyCell physiologyCellsChillsChronic Obstructive Airway DiseaseClinicalClinical ResearchClinical TrialsComputational algorithmComputer SimulationConnective Tissue DiseasesCryopreservationCryoprotective AgentsDefectDehydrationDevelopmentDiabetes MellitusDimethyl SulfoxideDiseaseDoseDroughtsDyspneaEnvironmentFailureFreezingGrowthHeartHeart ArrestHematopoietic stem cellsHumanHydration statusHypotensionIn VitroInfusion proceduresInvestigationIschemiaKidney DiseasesKidney FailureLimb structureLiteratureMarketingMeasuresMembraneMesenchymalMesenchymal Stem CellsMethodsModelingMolecular Mechanisms of ActionMultiple SclerosisMyocardial InfarctionNatureNauseaNeurologicOrganismOutcomeParkinson DiseasePathway interactionsPatient CarePatientsPhasePhase III Clinical TrialsPreservation TechniqueProcessProteinsProtocols documentationQuality ControlReactionReagentRiskSafetySiteSodium ChlorideSolutionsSpinal cord injuryStabilizing AgentsStressStrokeStromal CellsStructureSubcellular structureSuspension substanceSuspensionsTechnologyTemperatureTestingToxic effectTransportationTryptophan 2,3 Dioxygenasebiological systemscell typecellular imagingclinical applicationcommercial applicationgraft vs host diseasehigh throughput technologyimprovedmolecular dynamicsnervous system disordernew technologypolyolprotocol developmentpublic health relevanceresearch studyrespiratoryresponsescreeningsmall moleculesolutestemsugar
项目摘要
DESCRIPTION (provided by applicant): Cell therapy products is > $1 billion market with aggressive annual growth rates (15- 20%). Of all of the cells therapies currently in development, mesenchymal stem cells (MSCs) appear to have the greatest diversity of applications and potential for widespread use. Mesenchymal stem/stromal cells (MSCs) are being investigated for a variety of applications. Currently, over 200 clinical trials involve the use of MSCs and over
2000 patients have been safely treated with MSCs. MSCs are being investigated for treatment of cardiovascular disorders (stroke, myocardial infarction), diabetes, connective tissue disorders (cartilage defects, osteonecrosis, limb ischemia), chronic obstructive pulmonary disease, nervous system disorders (multiple sclerosis, Parkinson Disease, spinal cord injury), kidney diseases and more. Current methods for the preservation of MSCs are suboptimal. Improper methods of preservation are felt to have contributed to a recent failure of a Phase III clinical tral. In addition, the infusion of DMSO-containing cells is associated with adverse events that have been well documented in the clinical literature. Clinical and commercial application of MSCs will require the development of protocols that produce a consistent number of viable and functional cells. The proposed investigation transforms not only the preservation protocol for MSCs but creates a new paradigm by which preservation protocols for other cell types can be developed. We propose to use synergy between multiple preservation compounds to improve preservation outcome and replace conventional toxic cryoprotective agents such as DMSO. Testing solutions using multiple compounds would normally require thousands of experiments. We accelerate the convergence of the studies using a computational algorithm. Finally, we will use molecular dynamics to understand molecular mechanisms of action and rationally select compounds appropriate for testing. This type of approach will be applied first of all to MSCs but can be extended to a variety of different cell types used therapeutically. !
描述(由申请人提供):细胞治疗产品的市场价值 > 10 亿美元,年增长率极快 (15-20%)。在目前正在开发的所有细胞疗法中,间充质干细胞(MSC)似乎具有最大的应用多样性和广泛使用的潜力。间充质干/基质细胞 (MSC) 正在研究其多种应用。目前,已有 200 多项临床试验涉及 MSC 的使用
2000 名患者已接受 MSC 安全治疗。 MSC 正在研究用于治疗心血管疾病(中风、心肌梗死)、糖尿病、结缔组织疾病(软骨缺损、骨坏死、肢体缺血)、慢性阻塞性肺病、神经系统疾病(多发性硬化症、帕金森病、脊髓损伤)、肾脏疾病等。目前保存 MSC 的方法并不理想。人们认为,保存方法不当是导致最近 III 期临床试验失败的原因之一。此外,输注含 DMSO 的细胞与不良事件相关,这些不良事件已在临床文献中得到充分记录。间充质干细胞的临床和商业应用需要开发能够产生一致数量的活细胞和功能细胞的方案。拟议的研究不仅改变了 MSC 的保存方案,而且创建了一个新的范式,通过该范式可以开发其他细胞类型的保存方案。我们建议利用多种保存化合物之间的协同作用来改善保存效果并取代传统的有毒冷冻保护剂(如 DMSO)。使用多种化合物测试解决方案通常需要数千次实验。我们使用计算算法加速研究的收敛。最后,我们将利用分子动力学来了解分子作用机制并合理选择适合测试的化合物。这种类型的方法将首先应用于间充质干细胞,但可以扩展到治疗中使用的各种不同的细胞类型。 !
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALLISON HUBEL其他文献
ALLISON HUBEL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALLISON HUBEL', 18)}}的其他基金
Multicomponent solutions for the preservation of cell therapy products
用于保存细胞治疗产品的多组分解决方案
- 批准号:
10439717 - 财政年份:2017
- 资助金额:
$ 21.52万 - 项目类别:
Multicomponent solutions for the preservation of cell therapy products
用于保存细胞治疗产品的多组分解决方案
- 批准号:
10636645 - 财政年份:2017
- 资助金额:
$ 21.52万 - 项目类别:
Multicomponent solutions for the preservation of cell therapy products
用于保存细胞治疗产品的多组分解决方案
- 批准号:
10200145 - 财政年份:2017
- 资助金额:
$ 21.52万 - 项目类别:
Integrated training in development and clinical practice of cell-based therapies
细胞疗法开发和临床实践的综合培训
- 批准号:
9127354 - 财政年份:2015
- 资助金额:
$ 21.52万 - 项目类别:
Integrated training in development and clinical practice of cell-based therapies
细胞疗法开发和临床实践的综合培训
- 批准号:
9487293 - 财政年份:2015
- 资助金额:
$ 21.52万 - 项目类别:
Integrated training in development and clinical practice of cell-based therapies
细胞疗法开发和临床实践的综合培训
- 批准号:
9283633 - 财政年份:2015
- 资助金额:
$ 21.52万 - 项目类别:
Technology platform for development of multi-component preservation solution
多组分保存解决方案开发技术平台
- 批准号:
8703695 - 财政年份:2013
- 资助金额:
$ 21.52万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 21.52万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 21.52万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 21.52万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 21.52万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 21.52万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 21.52万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 21.52万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 21.52万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 21.52万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 21.52万 - 项目类别: